Cập nhật tình trạng kháng kháng sinh của Helicobacter pylori ở các bệnh nhân bệnh lý dạ dày tại Bệnh viện Trung ương Quân đội 108 giai đoạn 2019 đến 2022.

Helicobacter pylori (H. pylori) resistance is the most critical risk factor for eradication failure. This study aimed to update the H. pylori antibiotic resistance status over recent years. A total of 350 H. pylori strains were isolated from gastritis, peptic ulcer, and gastric cancer patients at Military Central Hospital 108 from 2019 to 2022. Antibiotic susceptibility tests were performed using the Epsilometer (E-test) technique. The resistance rates to AC, CH, MZ, LE, and TC were 30.6%, 44.6%, 44%, 33.4%, and 9.14%, respectively. The rates of double-, triple-, quadruple-, and quintupleantibiotic resistance among isolates were 33.1%, 15.1%, 4.3%, and 0.9%, respectively. The highest dual resistance rate was CH + MZ (19.7%), while the lowest was MZ + TC (4.9%). The strains showed a high level of resistance (MIC ≥ 256µg/mL) to CLR, 69.87% (109/156), MNZ, 73.37% (113/154), and (MIC ≥ 32µg/mL) to LE, 85.47% (100/117). MIC for AC and TC were low in most isolated strains. Most strains showed extremely high-level resistance of MZ, LE, and CH, while lowlevel resistance of TC and AC suggested that quadruple therapy, including tetracycline/amoxicillin, should be considered as an alternative strategy.